Targets of acinetobacter baumannii
Inventors
Urwyler, Simon • Haake, Markus • Rudolf, Michael
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10105432-B2
Publication Date
2018-10-23
Expiration Date
Abstract
The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.
Core Innovation
The disclosed invention relates to an Acinetobacter baumannii immunogenic composition that includes isolated recombinant antigenic polypeptides and/or isolated polypeptides encoded by recombinant nucleic acid molecules. The compositions are directed to generating or inducing an immune response against Acinetobacter baumannii in a subject in need thereof, using an immuno-effective amount of an adjuvant.
The document specifies antigenic targets through nucleic acid and polypeptide sequence definitions, including polynucleotides and encoded polypeptides identified by SEQ ID NOs. A notable antigenic feature includes an epitope motif represented by PVDFTVAI (SEQ ID NO:36), and the platform includes antigenic polypeptides such as FimA, CsuAB and OmpA as described in the included summary content.
The described approach supports feasibility by linking antigenic polypeptide targeting to conservation and breadth across clinical isolates and by assessing immunogenicity and functional activity in sera and in an Acinetobacter pneumonia mouse model. The document further describes identification of targets using Shedome analysis, comparative proteomics, and specific target identification using convalescent sera, and it supports use as vaccine, diagnostic, prophylactic, and therapeutic applications as described in the provided summary content.
Claims Coverage
The provided claim set contains three independent immunogenic-composition claims. Across these claims, the inventive features include a recombinant-nucleic-acid-encoded polypeptide with a specific nucleic acid sequence, an isolated recombinant antigenic polypeptide with the amino acid sequence of a specified SEQ ID, and use of an immuno-effective or effective amount of an adjuvant to generate, immunostimulate, and/or induce an immune response against Acinetobacter baumannii.
Recombinant nucleic acid-encoded polypeptide with adjuvant for Acinetobacter baumannii immune response
An immunogenic composition comprising an isolated polypeptide encoded by a recombinant nucleic acid molecule comprising a polynucleotide having the nucleic acid sequence of SEQ ID NO: 7, and an immuno-effective amount of an adjuvant, wherein the composition is effective in generating an immune response against Acinetobacter baumannii in a subject in need thereof.
Isolated recombinant antigenic polypeptide SEQ ID NO: 8 with immunostimulatory activity plus adjuvant
An immunogenic composition comprising an isolated recombinant antigenic polypeptide consisting of the amino acid sequence of SEQ ID NO: 8 having immunostimulatory activity in combination with an immuno-effective amount of an adjuvant.
Isolated recombinant antigenic polypeptide SEQ ID NO: 8 plus effective adjuvant to induce Acinetobacter baumannii response
An immunogenic composition comprising an isolated recombinant antigenic polypeptide comprising the amino acid sequence of SEQ ID NO: 8, and an effective amount of an adjuvant, wherein the composition induces an immune response against Acinetobacter baumannii.
Across the independent claims, the core claim coverage is an immunogenic composition built around a specified Acinetobacter baumannii antigenic polypeptide (SEQ ID NO: 8 at the amino-acid level, or a polypeptide encoded by a nucleic acid sequence such as SEQ ID NO: 7) combined with an adjuvant amount described as immuno-effective or effective. The intended functional outcome in the claims is generation, immunostimulation, and/or induction of an immune response against Acinetobacter baumannii in a subject.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?